The following are commonly asked questions and their answers about what happens after submitting a grant application and who to contact before and after the scientific review of the application.
The NIAMS clinical trials program is designed to support a range of studies from small first-in-human, tolerability or exploratory studies, to larger trials of efficacy or effectiveness. These FAQs apply to investigator-initiated clinical research grants only.
Carryover is the process by which unobligated funds remaining at the end of a budget period may be carried forward to the next budget period to cover allowable costs in that budget period. The carryover of funds enables grantees to use unexpended prior year grant funds in the current budget
The clinical study Principal Investigator (PI) safety monitoring responsibilities with respect to a Data and Safety Monitoring Board (DSMB) or Observational Study Monitoring Board (OSMB) ensure the study is conducted according to the highest scientific and ethical standards. Responsibilities are outlined in bold italics.
The NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. Clinical trials range from small
This document outlines the process by which requests for access to existing biospecimens from the OAI resource are processed, evaluated, and approved. Types of Specimen Available Type of Specimen Maximum Allowable Specimen Per Study Serum 0.15 ml (total of serum and plasma per study) EDTA plasma 0.15 ml (total of
Learn about the NIH and NIAMs requirements for data and safety monitoring, guidelines for creating a DSM plan, and types of DSM document review. The DSM may consist of a Data and Safety Monitoring Board (DSMB) or a Safety Officer (SO). The DSM bodies are advisory to the Institute Director
This Notice announces a change in the procedures by which the NIAMS considers requests for acceptance of grant applications that request $500,000 or more in direct costs for any project year. Background The most recent NIH policy on the acceptance of applications requesting direct costs of $500,000 or more for
Applying for a grant can be challenging—understanding the process can help. Learn the nuts and bolts of the NIH grant process, how the review process works, and how to prepare your grant application for success. About the NIH Grants Process Get an orientation to NIH funding, how the grants process
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.
PROMIS® developed pediatric measures for the functions, symptoms, behaviors, and feelings shown here. Self-report measures are used for children ages 5-17. Parent proxy-report measures are used for children ages 5-17. Measures are applicable to the general population and to those with chronic conditions.
December 2017 Word Version (DOC – 75 KB) PREFACE Investigators should consider using this template when developing the Data and Safety Monitoring Plan (DSMP) for clinical studies supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The goal of the DSMP is to provide a general